BioChimPharm’s journey has been featured in Forbes US December 2024 – January 2025 issue as part of the “World of Forbes” chapter.

“BioChimPharm’s leading medicine, Phagyo – developed from phades – is sold in 8000 pharmacies across nine countries to treat inflammatory infections like strep stroat.”

Building on the foundation of the world’s first historic phage factory (1934), at BioChimPharm we create and manufacture GMP-compliant phage pharmaceuticals for the treatment and prevention of antibiotic-resistant infections.